ONE ATTACK IS TOO MANY Live the difference. MONTH AFTER MONTH OF ZERO ATTACKS*

*In the open-label extension study of 63 patients aged 6 years and older treated with 60 IU/kg of HAEGARDA over an average of 1.5 years, the median time to first attack was 223 days. These results support the primary findings; however, the study was not designed in advance to measure the median days to first attack.

With HAEGARDA, HAE
attacks were reduced by

As a preventive therapy, HAEGARDA can effectively reduce the number of HAE attacks you experience.

^†In the clinical trial, the median reduction in number of attacks in people receiving HAEGARDA 60 IU/kg vs. placebo.

Use of rescue medication
was nearly eliminated by

You should always have HAE rescue medication available at all times in case of a breakthrough attack.

^‡In the clinical trial, the median reduction in rescue medication use in people receiving HAEGARDA 60 IU/kg vs. placebo.

LIVING THE DIFFERENCE

A long-term study followed patients in the U.S. who were treated with HAEGARDA for more than 12 months. Those people were, on average, attack free 99% of days while on treatment.

^§In the open-label extension study, a subgroup of 24 U.S. patients aged 6 years and older treated with 60 IU/kg of HAEGARDA for >12 months were on average attack free for 99% of days while on treatment.

Talk to your doctor

about how HAEGARDA can reduce the risk of HAE attacks

USE OUR GUIDE

HAEGARDA TREATS YOUR DISEASE, NOT JUST YOUR SYMPTOMS

The biggest difference since taking HAEGARDA is that for the first time in my life, I have a glimpse of what normal is. That feels good.

–Machelle, Started HAEGARDA in 2017

The root cause of HAE is missing or nonworking C1 esterase inhibitor (C1-INH), a key protein in your body that controls swelling

HAE attacks

can occur when your levels of working C1-INH are too low or not functional (nonworking)

HAEGARDA adds

working C1-INH to your body

HAEGARDA brings your working C1-INH levels back up

and closer to normal, reducing the risk of an HAE ATTACK

See in more detail how HAEGARDA works

HAEGARDA SAFETY AND SIDE EFFECTS

In a 32-week clinical trial, side effects for people taking HAEGARDA were mostly mild

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling), hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA.

HAEGARDA HAS BEEN PROVEN SAFE AND EFFECTIVE FOR DIFFERENT PATIENT TYPES

HAEGARDA is approved for use in adults, and in children 6 years and older

Talk to your doctor about how HAEGARDA can be an effective and safe therapy for children

The safety and effectiveness of HAEGARDA were evaluated in subgroups within both short- and long-term clinical trials. These subgroups, part of the larger studies, consisted of nine patients, 8 to <17 years of age. Results within this age group were consistent with overall study results

See checklists that can help you navigate HAE throughout specific stages of life

DOWNLOAD NOW

Before taking any HAE therapies, consult with your doctor if you are pregnant or considering becoming pregnant

In a long-term study, four pregnant women with type I HAE and ranging in age from 19 to 32 years received HAEGARDA. These women received 40–60 IU/kg per subcutaneous administration for 4–8 weeks (9–15 doses) during the first trimester. These women reported no complications during delivery, and all women delivered healthy babies^||

Women often experience HAE differently than men do

UNDERSTAND WHY

Please refer to section 8 of the prescribing information for additional data on the use of C1-INH during pregnancy and lactation.

^‖Due to study protocols, these patients were not eligible to continue the trial beyond the first trimester.

The World Allergy Organization Recommends C1-INH as the Preferred Therapy During Pregnancy and Adolescence.

Committed to Quality Manufacturing

We understand that you want the medications you take to meet the highest safety and quality standards. That’s why HAEGARDA goes through an advanced screening and purification process to reduce the risk of transmitting infection.

We are committed to producing high-quality, safe, and effective medicines. To us, that means that each step of the manufacturing process must meet or exceed the most stringent international standards for product safety in accordance with regulatory agencies worldwide.^¶

^¶The risk of transmission of infectious agents cannot be completely eliminated.

Our commitment includes:

Providing a consistent supply of HAEGARDA to all patients who start on HAEGARDA

Having in-place systems of collection, manufacturing, and distribution that meet high quality and safety standards

Producing high-quality, safe, and effective biotherapies with no confirmed transmissions of viruses with C1-INH therapies in the U.S.

Our manufacturing process includes:

Carefully selecting and screening US plasma donors

Thorough testing for viruses

Pasteurization (heat treatment for 10 hours)

Virus nanofiltration with 2 different-sized filters

SEE HOW OUR PRODUCTS ARE MADE

READY TO TALK WITH YOUR DOCTOR?

We want to make sure you have what you need to have a productive conversation with your doctor about HAE and about HAEGARDA.

Start the discussion off right

Be prepared and ask the right questions. Use this Doctor Discussion Guide to help you get started and to ensure you cover all the points you need during your visit.